A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma
NCT02993731
Completed
This is a randomized, open-label, multi-center, phase 3 study of napabucasin plus weekly nab-paclitaxel with gemcitabine versus weekly nab-paclitaxel with gemcitabine for adult patients with Metastatic Pancreatic Ductal Adenocarcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/13/2023
Locations: Comprehensive Blood and Cancer Center, Bakersfield, California +7 locations
Conditions: Carcinoma, Pancreatic Ductal
Register for Updates
Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)
NCT02584478
Active Not Recruiting
This trial is a Phase 1b/2a/3 trial designed to evaluate the safety and efficacy of adding oral AL3818 (Anlotinib, INN: Catequentinib), a Dual Receptor Tyrosine Kinase Inhibitor, to standard platinum-based chemotherapy concurrently in Subjects with Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/07/2023
Locations: The Oncology Institute of Hope and Innovation, Long Beach, California
Conditions: Endometrial Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Cervical Carcinoma
Register for Updates
A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab
NCT02013154
Completed
A study to evaluate the safety and tolerability of DKN-01 in combination with weekly paclitaxel or pembrolizumab in participants with relapsed or refractory Esophagogastric Malignancies
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/30/2023
Locations: Cedars Sinai Medical Care Foundation, Los Angeles, California
Conditions: Esophageal Neoplasms, Adenocarcinoma of the Gastroesophageal Junction, Gastroesophageal Cancer, Squamous Cell Carcinoma, Gastric Adenocarcinoma
Register for Updates
Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
NCT04329949
Terminated
This is a Phase 3, open-label study to evaluate the objective response rate (ORR), in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with relacorilant in combination with nab-paclitaxel, according to blinded independent central review.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/26/2023
Locations: Site #171, Duarte, California +1 locations
Conditions: Metastatic Pancreatic Ductal Adenocarcinoma
Register for Updates
Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma
NCT04983407
Terminated
This is a Phase 1b/2 study of batiraxcept (AVB-S6-500) designed to evaluate the safety and efficacy of batiraxcept in combination with nab-paclitaxel and gemcitabine in subjects with locally advanced, recurrent, or metastatic pancreatic adenocarcinoma as first line therapy. The phase 1b portion of the study is open label and patients will receive batiraxcept, nab-paclitaxel, and gemcitabine. The Phase 2 portion of the study is randomized, 2-arm, open-label study to compare efficacy and tolerabil... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/26/2023
Locations: UCLA Health, Santa Monica, California
Conditions: Pancreatic Adenocarcinoma
Register for Updates
A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors
NCT04247126
Completed
The study consists of 2 parts. Part 1 is dose escalation and will first administer SY-5609 alone to participants with select advanced solid tumors and then in combination with fulvestrant to participants with HR positive, HER2-negative breast cancer. Part 2 is a dose expansion and will first administer SY-5609 in combination with gemcitabine and then SY-5609 in combination with gemcitabine and nab-paclitaxel in participants with pancreatic ductal adenocarcinoma (PDAC) .
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/26/2023
Locations: Cedars-Sinai Medical Center, Los Angeles, California +1 locations
Conditions: Advanced Solid Tumor, Breast Cancer, Small-cell Lung Cancer, Pancreatic Cancer
Register for Updates
Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer
NCT04729608
Terminated
This is a randomized, double-blind Phase 3 study to compare the efficacy and safety of batiraxcept (AVB-S6-500) in combination with paclitaxel (PAC) versus placebo in combination with PAC in patients with platinum resistant recurrent ovarian cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/26/2023
Locations: Disney Family Cancer Center, Burbank, California +6 locations
Conditions: Platinum-resistant Ovarian Cancer
Register for Updates
A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer
NCT03197935
Completed
This is a global Phase III, double-blind, randomized, placebo-controlled study designed to evaluate the efficacy and safety of neoadjuvant treatment with atezolizumab (anti-programmed death-ligand 1 \[anti-PD-L1\] antibody) and nab-paclitaxel followed by doxorubicin and cyclophosphamide (nab-pac-AC), or placebo and nab-pac-AC in participants eligible for surgery with initial clinically assessed triple-negative breast cancer (TNBC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/23/2023
Locations: Stanford University Medical Center, Palo Alto, California
Conditions: Triple-negative Breast Cancer
Register for Updates
Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )
NCT03748134
Completed
This is a randomized, double-blind multi-center, phase III study comparing the efficacy and safety of sintilimab or placebo in combination with chemotherapy as first-line treatment in subjects with unresectable, locally advanced recurrent or metastatic esophageal squamous cell carcinoma. After the interim analysis conducted by the iDMC, an open-label assignment of experimental arm therapy will continue in regions outside of China, in order to further evaluate the efficacy and safety of sintilim... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
10/22/2023
Locations: St. Joseph Heritage Healthcare - Virginia K. Crosson Cancer Center, Anaheim, California +1 locations
Conditions: Esophageal Squamous Cell Carcinoma
Register for Updates
Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer
NCT01522768
Completed
The purpose of this study is to find out what effects, good or bad, the combination of standard chemotherapy agent paclitaxel with the investigational (experimental) drug afatinib that targets HER2, has on HER2-positive esophagogastric cancer that started to get bigger despite previous treatment with trastuzumab. The doctors will also study the tumor to understand why it grew while on trastuzumab treatment and to see the effects afatinib and paclitaxel has on the tumor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/11/2023
Locations: University of Southern California, Los Angeles, California
Conditions: Esophageal Cancer, Gastric Cancer
Register for Updates
Phase 2 Study IV QUZYTTIR™ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine
NCT04189588
Completed
This study is designed to compare the number of infusion reactions to treatment with an anti-CD20 such as Rituxan® (rituximab) or Taxol® (Paclitaxel) after premedication with intravenous (IV) QUZYTTIR™ cetirizine hydrochloride (HCl) or IV diphenhydramine during first-cycle infusion or re-treatment with an anti-CD20 such as Rituxan® (rituximab) or Paclitaxel. Re-treatment is defined as re-treatment with an anti-CD20 such as Rituxan® (rituximab) or Paclitaxel after 6 months or in patients with per... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/04/2023
Locations: St.Joseph Heritage Care, Napa, California +2 locations
Conditions: Oncology Patients Receiving Chemotherapy
Register for Updates
TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers
NCT03884556
Completed
This is a phase 1/1b study of TTX-030, an antibody that inhibits CD39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of immunosuppressive adenosine, which may change the tumor microenvironment and promote anti-tumor immune response. This trial will study the safety, tolerability, pharmacokinetics, and anti-tumor activity of TTX-030 as a single agent and in combination with an approved anti-PD-1 immunotherapy and standard chemotherapies... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/02/2023
Locations: UC Irvine Cancer Center, Orange, California +2 locations
Conditions: Solid Tumor, Lymphoma
Register for Updates